Pfizer’s Phase III trial studying the investigational compound axitinib in previously treated patients with metastatic renal cell carcinoma (mRCC) met its primary endpoint, demonstrating significantly extended progression-free survival (PFS) when compared to sorafenib. Additionally, axitinib demonstrated a generally manageable safety profile in this study. “It is gratifying that in this trial axitinib provided significant benefit to patients with advanced RCC whose disease had progresse...